<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39346561</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Neratinib safety evaluation: real-world adverse event analysis from the FAERS database.</ArticleTitle><Pagination><StartPage>1425171</StartPage><MedlinePgn>1425171</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1425171</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2024.1425171</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="UNASSIGNED">Neratinib has emerged as significant theraputic option for breast cancer treatment. However, despite its approval, numerous adverse drug events (ADEs) associated to it remain unrecognized and unreported. This study aims to mine and analyze the signals of ADEs related to neratinib from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database, providing insights for safe and rational clinical use of drug.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">All the neratinib-related ADEs data were collected from FAERS database from the third quarter (Q3) of 2017 to the fourth quarter (Q4) of 2023. After standardizing the data, 4 disproportionality methods were used to assess the correlation between neratinib and ADEs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Of the 1,544 ADEs implicating neratinib as the primary suspected drug, a combined total of 48 preferred terms (PTs) and 10 system organ classes (SOCs) showed significant disproportionality accross all four algorithms simultaneously. These SOCs included gastrointestinal disorders (n = 2,564, ROR 7.14), general disorders and administration site conditions (n = 958, ROR 0.77) and injury poisoning and procedural complications (n = 474, ROR 0.58) among others. Upon comparison with the neratinib manual, 34 ADEs not documented in the manual were found at the PT level.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Our study provide new real-world evidence for drug safety information of neratinib. While the majority of our findings were aligned with the information provided in the manual. We identified additional ADEs not previously documented. Consequently, further studies are needed to validate unreported ADEs to ensure the efficacy and safety of neratinib for patients.</AbstractText><CopyrightInformation>Copyright © 2024 Fan, Wu, Xu, Yang, An, Zhang, Abbas and Dong.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Yunhe</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Teng</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Pengyang</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Chuanli</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Environmental Medical Engineering and Education Ministry, School of Public Health, Southeast University, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Preventive Medicine, School of Public Health, Southeast University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Haijia</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abbas</LastName><ForeName>Mureed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Modern Research Center for Traditional Chinese Medicine, the Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education, Shanxi University, Taiyuan, Shanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Xiushan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FAERS</Keyword><Keyword MajorTopicYN="N">adverse drug events</Keyword><Keyword MajorTopicYN="N">disproportionality methods</Keyword><Keyword MajorTopicYN="N">neratinib</Keyword><Keyword MajorTopicYN="N">safety signal</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>9</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39346561</ArticleId><ArticleId IdType="pmc">PMC11427278</ArticleId><ArticleId IdType="doi">10.3389/fphar.2024.1425171</ArticleId><ArticleId IdType="pii">1425171</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amberg N., Sotiropoulou P. A., Heller G., Lichtenberger B. M., Holcmann M., Camurdanoglu B., et al. (2019). EGFR controls hair shaft differentiation in a p53-independent manner. iScience 31 (15), 243–256. 10.1016/j.isci.2019.04.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2019.04.018</ArticleId><ArticleId IdType="pmc">PMC6515155</ArticleId><ArticleId IdType="pubmed">31082735</ArticleId></ArticleIdList></Reference><Reference><Citation>Bate A., Lindquist M., Edwards I. R., Olsson S., Orre R., Lansner A., et al. (1998). A Bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 54, 315–321. 10.1007/s002280050466</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s002280050466</ArticleId><ArticleId IdType="pubmed">9696956</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown E. G. (2004). Using MedDRA: implications for risk management. Drug Saf. 27 (8), 591–602. 10.2165/00002018-200427080-00010</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00002018-200427080-00010</ArticleId><ArticleId IdType="pubmed">15154830</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan A., Moy B., Mansi J., Ejlertsen B., Holmes F. A., Chia S., et al. (2021). Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial. Clin. Breast Cancer 21 (1), 80–91.e7. 10.1016/j.clbc.2020.09.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clbc.2020.09.014</ArticleId><ArticleId IdType="pubmed">33183970</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks E. D. (2017). Neratinib: first global approval. Drugs 77 (15), 1695–1704. 10.1007/s40265-017-0811-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-017-0811-4</ArticleId><ArticleId IdType="pubmed">28884417</ArticleId></ArticleIdList></Reference><Reference><Citation>DuMouchel W. (1999). Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am. Stat. 53 (3), 177–190. 10.2307/2686093</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2686093</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehmann L. M., Ruzicka T., Wollenberg A. (2011). Cutaneous side-effects of EGFR inhibitors and their management. Skin. Ther. Lett. 16 (1), 1–3.</Citation><ArticleIdList><ArticleId IdType="pubmed">21293833</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans S. J. W., Waller P. C., Davis S. (2001). Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. 10 (6), 483–486. 10.1002/pds.677</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.677</ArticleId><ArticleId IdType="pubmed">11828828</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi N., Das G. M. (2019). Metabolic reprogramming in breast cancer and its therapeutic implications. Cells 26 (2), 89. 10.3390/cells8020089</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8020089</ArticleId><ArticleId IdType="pmc">PMC6406734</ArticleId><ArticleId IdType="pubmed">30691108</ArticleId></ArticleIdList></Reference><Reference><Citation>Giordano S. H., Franzoi M. A. B., Temin S., Anders C. K., Chandarlapaty S., Crews J. R., et al. (2022). Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update. J. Clin. Oncol. 10 (23), 2612–2635. 10.1200/JCO.22.00519</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.22.00519</ArticleId><ArticleId IdType="pubmed">35640077</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L., Shao W., Zhou C., Yang H., Yang L., Cai Q., et al. (2023). Neratinib for HER2-positive breast cancer with an overlooked option. Mol. Med. 6 (1), 134. 10.1186/s10020-023-00736-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-023-00736-0</ArticleId><ArticleId IdType="pmc">PMC10559443</ArticleId><ArticleId IdType="pubmed">37803271</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamid R. N., Ahn C. S., Huang W. W. (2019). Adverse cutaneous effects of neratinib. J. dermatological Treat. 30 (5), 487–488. 10.1080/09546634.2018.1536253</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09546634.2018.1536253</ArticleId><ArticleId IdType="pubmed">30321080</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M. Y. (2021). Breast cancer metastasis. Adv. Exp. Med. Biol. 1187, 183–204. 10.1007/978-981-32-9620-6_9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-981-32-9620-6_9</ArticleId><ArticleId IdType="pubmed">33983579</ArticleId></ArticleIdList></Reference><Reference><Citation>Malmgren J. A., Atwood M. K., Kaplan H. G. (2023). Persistence of patient-detected breast cancer over time: 1990-2019. Cancer 15 (24), 3862–3872. 10.1002/cncr.34973</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.34973</ArticleId><ArticleId IdType="pubmed">37552155</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgovan C., Dobrea C. M., Butuca A., Arseniu A. M., Frum A., Rus L. L., et al. (2024). Safety profile of the trastuzumab-based ADCs: analysis of real-world data registered in EudraVigilance. Biomedicines 25 (5), 953. 10.3390/biomedicines12050953</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines12050953</ArticleId><ArticleId IdType="pmc">PMC11117560</ArticleId><ArticleId IdType="pubmed">38790915</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanba D., Toki F., Asakawa K., Matsumura H., Shiraishi K., Sayama K., et al. (2021). EGFR-mediated epidermal stem cell motility drives skin regeneration through COL17A1 proteolysis. J. Cell Biol. 220 (11), e202012073. 10.1083/jcb.202012073</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.202012073</ArticleId><ArticleId IdType="pmc">PMC8563287</ArticleId><ArticleId IdType="pubmed">34550317</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman K. J., Lanes S., Sacks S. T. (2004). The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol. Drug Saf. 13 (8), 519–523. 10.1002/pds.1001</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.1001</ArticleId><ArticleId IdType="pubmed">15317031</ArticleId></ArticleIdList></Reference><Reference><Citation>Scully O. J., Bay B. H., Yip G., Yu Y. (2012). Breast cancer metastasis. Cancer Genomics Proteomics 9 (5), 311–320. 10.1007/978-981-32-9620-6_9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-981-32-9620-6_9</ArticleId><ArticleId IdType="pubmed">22990110</ArticleId></ArticleIdList></Reference><Reference><Citation>Slamon D. J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344 (11), 783–792. 10.1056/NEJM200103153441101</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200103153441101</ArticleId><ArticleId IdType="pubmed">11248153</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung H., Ferlay J., Siegel R. L., Laversanne M., Soerjomataram I., Jemal A., et al. (2021). Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for36 cancers in 185 countries. A Cancer J. Clin. 71 (3), 209–249. 10.3322/caac.21660</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21660</ArticleId><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiwari S. R., Mishra P., Abraham J. (2016). Neratinib, A novel HER2-targeted tyrosine kinase inhibitor. Clin. Breast Cancer 16 (5), 344–348. 10.1016/j.clbc.2016.05.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clbc.2016.05.016</ArticleId><ArticleId IdType="pubmed">27405796</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahdan-Alaswad R., Liu B., Thor A. D. (2020). Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem. Cancer Drug Resist 3 (2), 179–198. 10.20517/cdr.2019.92</Citation><ArticleIdList><ArticleId IdType="doi">10.20517/cdr.2019.92</ArticleId><ArticleId IdType="pmc">PMC9090587</ArticleId><ArticleId IdType="pubmed">35582612</ArticleId></ArticleIdList></Reference><Reference><Citation>Yunusa I., Teng C., Karaye I. M., Crounse E., Alsahali S., Maleki N. (2022). Comparative safety signal assessment of hospitalization associated with the use of atypical antipsychotics. Front. Psychol. 13, 917351. 10.3389/fpsyt.2022.917351</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2022.917351</ArticleId><ArticleId IdType="pmc">PMC9207238</ArticleId><ArticleId IdType="pubmed">35733796</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z., Hultgren K. E. (2020). Complementing the us food and drug administration adverse event reporting system with adverse drug reaction reporting from social media: comparative analysis. JMIR Public Health Surveill. 6 (3), e19266. 10.2196/19266</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/19266</ArticleId><ArticleId IdType="pmc">PMC7557434</ArticleId><ArticleId IdType="pubmed">32996889</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>